AHK-Cu 50mg – Research Grade Copper Peptide

AHK-Cu is a small synthetic tripeptide-copper complex consisting of the three amino acids alanine, histidine, and lysine (in that order — hence "AHK") bound non-covalently to a single copper(II) ion. It belongs to a small family of copper-binding peptides that have been studied in dermatology-related research for decades, alongside its better-known relative GHK-Cu (the glycyl-L-histidyl-L-lysine copper complex). The two peptides share the central histidine residue that anchors copper coordination and share a general conceptual framework for how small copper-peptide complexes interact with cells in research models, but they have distinct sequences and somewhat distinct research applications.

The scientific interest in AHK-Cu sits at the intersection of two areas: the broader biology of copper-peptide complexes as cell-signaling molecules and metal-delivery systems, and the specific biology of the hair follicle and dermal papilla cells that has emerged as a focus of dermatology-related research on small copper peptides. Published research on AHK-Cu specifically — though smaller in volume than the literature on GHK-Cu — has explored effects on dermal papilla cells, hair-follicle biology, and related research themes in cell-culture systems and in animal-model investigations.

This page is a plain-English educational reference for readers who want to understand what AHK-Cu actually is, how it relates to other copper-peptide complexes, what the published research describes about its laboratory characterization, and where it sits in the broader research peptide landscape. It is not a medical guide, it does not describe a treatment for hair loss or any other condition, and it makes no claims about effects in people. AHK-Cu is a research peptide complex supplied for laboratory and analytical purposes only, and the entire discussion below is framed within that context.

A second goal of this page is to draw a clean line between AHK-Cu and the related copper peptides with which it is sometimes confused, particularly GHK-Cu and the broader category of "copper peptides" sometimes mentioned in popular cosmetic literature. The three letters in each name refer to the amino acid sequence — GHK is glycine-histidine-lysine, AHK is alanine-histidine-lysine — and the "-Cu" suffix indicates the copper coordination that distinguishes the metal complex from the free uncomplexed peptide. Each variant has its own research history and its own scope of published characterization.

Throughout the page, technical terms that show up repeatedly in copper-peptide research are defined when they appear. Terms like "tripeptide," "copper coordination," "dermal papilla cell," "hair follicle," and "metal-peptide complex" appear constantly in the primary literature. The glossary at the end of the page collects all of them for easy reference, and the FAQ section addresses the questions that most often arise from students, hobbyists, and laboratory staff encountering the compound for the first time.

AHK-Cu is a synthetic tripeptide-copper complex with the chemical composition Ala-His-Lys plus a coordinated copper(II) ion. The three amino acids — alanine (Ala), histidine (His), and lysine (Lys) — are linked by standard peptide bonds in the order N-terminal alanine, central histidine, C-terminal lysine. The copper(II) ion is held in place by coordination to specific donor atoms on the peptide, particularly the imidazole nitrogen of the histidine side chain and the amide nitrogens of the peptide backbone, in a defined geometry that has been characterized in the broader copper-peptide research literature.

The tripeptide portion of the molecule — Ala-His-Lys without the copper — is a small linear peptide with a molecular mass of approximately 354 daltons in its free form. With the coordinated copper(II) and the counter-ions or water molecules that complete the coordination sphere, the molecular composition of AHK-Cu varies depending on the specific stoichiometry and preparation method, but the active species is the copper-coordinated tripeptide. The copper ion is what distinguishes the metal complex from the free uncomplexed peptide and is what defines the molecule's identity in research contexts.

The copper coordination chemistry of AHK-Cu is part of a broader area of bioinorganic chemistry concerning small copper-binding peptides. Histidine is a particularly effective copper-coordinating amino acid because its imidazole side chain provides a nitrogen donor atom that binds copper with high affinity. Many biological copper-binding sites in proteins involve histidine residues; the small peptide GHK-Cu and AHK-Cu are designed in part as small mimics of this general copper-coordination motif. The detailed coordination geometry of AHK-Cu, including the contribution of the lysine side chain to the overall structure, has been the subject of bioinorganic characterization in the published literature.

In research contexts, AHK-Cu has been studied primarily in cell-culture systems and in animal-model investigations. The most heavily studied application area is dermatology-related research, particularly research on dermal papilla cells — the specialized cells at the base of hair follicles that play important roles in hair-follicle biology — and on related cell types in the skin and hair-follicle ecosystem. The published research has explored effects on cell signaling, on gene expression, and on cell-culture morphology and growth in these systems. This research informs basic biology of dermal cell types rather than producing clinical recommendations.

AHK-Cu is produced for research use through standard solid-phase peptide synthesis of the tripeptide portion, followed by complexation with a copper(II) salt under controlled conditions to produce the copper-coordinated complex. Purification and characterization use standard analytical chemistry techniques including reversed-phase HPLC, mass spectrometry, and spectroscopic methods sensitive to the copper coordination (such as UV-visible absorption spectroscopy, which produces a characteristic absorption band for the copper(II)-peptide complex). The final product is supplied as a powder, often with a characteristic blue or purple-blue color from the copper-peptide complex.

It is worth being specific about what AHK-Cu is not. It is not a hair-loss treatment or a cosmetic ingredient with established clinical efficacy — it is a research peptide complex used in laboratory and analytical research. It is not GHK-Cu, although it shares the general category of small copper-binding peptides and the central histidine coordination motif. It is not a growth hormone secretagogue, a GHRH analog, or a metabolic-research peptide; it belongs to its own conceptual category as a small copper-binding tripeptide with dermatology-related research applications. As a research peptide, it is intended for laboratory and analytical work and is not a medicine, supplement, or approved therapy in any jurisdiction.

The history of AHK-Cu is best understood within the broader history of copper-peptide research, which begins with the work of Loren Pickart and colleagues in the 1970s on the small copper-binding tripeptide GHK-Cu. Pickart identified GHK (glycyl-L-histidyl-L-lysine) as a copper-binding peptide isolated from human blood plasma and characterized its copper-binding properties and its effects in various cell-culture and animal-model systems. The early work on GHK-Cu established the conceptual framework for thinking about small copper-binding peptides as bioactive molecules and provided the methodological foundation for subsequent research on related peptide-copper complexes.

The GHK-Cu literature grew substantially through the 1980s, 1990s, and 2000s, exploring the peptide's effects in wound-healing research models, in dermatology-related cell-culture systems, and in various other research contexts. Several other small copper-binding peptides — including AHK-Cu (alanine-histidine-lysine), GHL (glycyl-histidyl-leucine), and related sequences — were investigated alongside GHK-Cu in comparative studies, with the goal of understanding how the specific amino acid composition influences copper coordination, cellular uptake, and biological activity in research models.

AHK-Cu itself emerged as a focus of research interest particularly in the dermatology-related context of hair-follicle and dermal papilla cell biology. The published research on AHK-Cu has been smaller in volume than the literature on GHK-Cu, but the peptide has appeared in basic-research investigations of dermal papilla cell signaling, in studies of hair-follicle biology in cell-culture and animal-model systems, and in comparative research alongside GHK-Cu and other small copper peptides. The specific scientific interest in AHK-Cu over GHK-Cu in some dermatology-related contexts reflects the differences in sequence and the slightly different research-model findings reported in published comparative work.

The broader commercial and cosmetic interest in copper peptides — primarily focused on GHK-Cu, but extending to other small copper-binding peptides including AHK-Cu — emerged in the 1990s and 2000s and has continued to the present. Some copper peptide ingredients have appeared in cosmetic product formulations, and various claims have been made in popular cosmetic literature about the effects of copper peptides on skin and hair appearance. From a research perspective, however, the conventional pharmaceutical or medical evidence base for AHK-Cu specifically is limited, with the published work concentrated in basic-research investigations and cosmetic-research contexts rather than in approved-medicine clinical-development programs.

Important milestones in the AHK-Cu literature include the foundational work on GHK-Cu by Loren Pickart in the 1970s that established the broader copper-peptide research framework, the subsequent comparative work on related small copper-binding peptides including AHK-Cu through the 1980s and 1990s, the specific research interest in AHK-Cu in dermal papilla cell and hair-follicle biology that has continued to the present, and the ongoing use of the compound as a research peptide complex in basic-research investigations.

The science of AHK-Cu is anchored in three areas: the bioinorganic chemistry of copper-peptide coordination, the cell biology of dermal papilla cells and the hair-follicle ecosystem, and the broader literature on small copper-binding peptides as cell-signaling molecules in research models. The compound sits at the intersection of these areas, and understanding its place requires looking at each briefly.

Copper is an essential trace element in biology, with roles in many enzymatic and structural systems throughout the body. Copper binding by proteins typically involves specific donor atoms — particularly the imidazole nitrogen of histidine residues, the thiolate sulfur of cysteine residues, and the amide nitrogens of the peptide backbone — arranged in defined geometric arrangements around the copper ion. Small peptides containing histidine residues can mimic some aspects of natural copper-binding sites in proteins, and the small copper-peptide complexes GHK-Cu and AHK-Cu have been studied in part as small synthetic copper-binding systems with defined chemistry.

The AHK-Cu complex specifically involves coordination of the copper(II) ion by donor atoms on the tripeptide, including the histidine imidazole nitrogen and the deprotonated amide nitrogens of the peptide backbone. The detailed coordination geometry has been characterized by bioinorganic methods including UV-visible absorption spectroscopy, electron paramagnetic resonance spectroscopy, and other techniques sensitive to copper coordination. The characteristic blue or purple-blue color of the AHK-Cu complex arises from the d-d electronic transitions of the copper(II) ion in the peptide coordination environment.

• AHK-Cu is a tripeptide-copper complex consisting of alanine-histidine-lysine coordinated to a copper(II) ion.
• Copper coordination involves the histidine imidazole nitrogen and the deprotonated amide nitrogens of the peptide backbone.
• Most published research has focused on effects in dermal papilla cells and hair-follicle biology in research models.
• Comparative work with GHK-Cu and other small copper-binding peptides places AHK-Cu in the broader copper-peptide research family.
• The detailed mechanism of cellular effects — copper delivery versus peptide-specific signaling — is not fully resolved.

Structurally, AHK-Cu consists of a small tripeptide — Ala-His-Lys — coordinated to a copper(II) ion. The tripeptide portion has the sequence: N-terminal alanine, central histidine, C-terminal lysine, with standard peptide bonds linking the three amino acids. The free uncomplexed tripeptide has a molecular mass of approximately 354 daltons. With the coordinated copper(II) and the additional ligands or counter-ions that may be present in the solid form, the molecular composition of AHK-Cu varies depending on the preparation, but the active species in solution is the copper-coordinated tripeptide.

The copper(II) ion in AHK-Cu is held in place by coordination to multiple donor atoms from the peptide. The histidine imidazole side chain provides one of the strongest nitrogen donor atoms, anchoring the copper in a defined position relative to the peptide chain. The deprotonated amide nitrogens of the peptide backbone — the nitrogen atoms of the peptide bonds — provide additional nitrogen donors that contribute to the coordination geometry. The lysine side chain, with its amino group, may participate in the coordination geometry directly or may influence the structure indirectly through electrostatic and hydrogen-bonding interactions. The detailed coordination geometry has been characterized by bioinorganic methods in the broader copper-peptide research literature.

One of the practical consequences of the copper coordination is the characteristic color of AHK-Cu solutions and powders, which is typically blue or purple-blue. The color arises from the d-d electronic transitions of the copper(II) ion in the peptide coordination environment and produces a characteristic absorption band in the visible region of the UV-visible spectrum, typically around 525-550 nm depending on the specific coordination geometry. The characteristic color is a useful indicator of the formation of the copper-peptide complex during preparation and characterization.

The stability of the AHK-Cu complex is governed by the binding affinity of the copper(II) ion for the tripeptide. The stability constant is high under physiological conditions, meaning that the copper ion is firmly held by the peptide and is not readily exchanged with other copper-binding species in solution. The defined stoichiometry — typically one copper per tripeptide — distinguishes the well-formed complex from non-specific copper-peptide interactions.

In terms of practical preparation, AHK-Cu is produced for research use through a two-step process. First, the tripeptide Ala-His-Lys is synthesized by standard solid-phase peptide synthesis using Fmoc protecting-group chemistry, then purified by reversed-phase HPLC. Second, the purified tripeptide is complexed with a copper(II) salt under controlled conditions (typically with a slight excess of copper, in a defined buffer at controlled pH) to produce the copper-coordinated complex. The complex is then purified or isolated and characterized by analytical methods including mass spectrometry and UV-visible absorption spectroscopy.

A Certificate of Analysis from a reputable supplier reports the tripeptide sequence, the measured molecular mass, the HPLC purity, the copper content, and ideally also confirmation of the copper-peptide complex formation by spectroscopic characterization. The copper content is particularly important because the active species is the copper-coordinated form, not the free uncomplexed tripeptide. Stability of the lyophilized complex stored sealed at refrigerated or freeze temperatures away from light is generally considered good for extended periods.

AHK-Cu has been used as a research tool across a focused set of laboratory themes, primarily in dermatology-related cell biology and in comparative copper-peptide research. None of the areas described below represents an established therapeutic use of AHK-Cu in humans, and none should be read as suggesting clinical benefit for hair loss, dermatological conditions, or any other indication. They are research directions where the compound has been useful as a defined experimental probe.

• Dermal papilla cell culture research
• Hair-follicle biology in cell-culture and animal-model systems
• Comparative pharmacology across the small copper-peptide family
• Cell-signaling and gene-expression studies in dermatology-related cell types
• Bioinorganic chemistry of small copper-binding peptides

AHK-Cu is most usefully compared with other members of the small copper-peptide family, particularly GHK-Cu, and with broader categories of dermatology-related research compounds. The table below highlights the key distinctions.

The most direct comparison is with GHK-Cu, the glycyl-histidyl-lysine copper complex that is the most extensively studied member of the small copper-peptide family. The two peptides differ in a single amino acid — glycine versus alanine at the N-terminus — and share the central histidine residue that anchors copper coordination and the C-terminal lysine. The published research literature on GHK-Cu is substantially larger than the literature on AHK-Cu, and the two compounds have somewhat different research-application emphases: GHK-Cu has been studied more in wound-healing research, while AHK-Cu has been studied more in dermal papilla cell and hair-follicle research. The two compounds are conceptually related but pharmacologically distinct in detail.

A broader comparison is with the general category of copper-binding peptides used in research, which includes other small synthetic peptides as well as natural copper-binding proteins and peptide-derived sequences. Each member of this broader family has its own specific chemistry and research applications.

In dermatology-related research, AHK-Cu can also be compared conceptually with other research compounds studied in dermal papilla cell and hair-follicle biology. These other compounds work through entirely different mechanisms — they are not copper-peptide complexes — and they belong to different research categories. The point of comparison is to clarify that AHK-Cu occupies a specific position within the small copper-peptide research family and should not be conflated with unrelated dermatology-related research compounds.

Finally, AHK-Cu should be distinguished from broader categories of peptides that share no chemical or conceptual relationship with the copper-peptide family. It is not a growth hormone secretagogue, a GHRH analog, a ghrelin-receptor agonist, or a metabolic-research peptide. It belongs specifically to the small copper-peptide research category.

The AHK-Cu literature gives a particular impression: a small copper-binding tripeptide-copper complex with a clear chemical identity, a focused but limited body of published research, and a specific research niche in dermal papilla cell and hair-follicle biology. The compound sits within the broader copper-peptide research family that has been developed since the foundational work on GHK-Cu by Loren Pickart in the 1970s, sharing the central conceptual framework of small histidine-containing peptides serving as copper-binding bioactive complexes in research models.

The bioinorganic chemistry of AHK-Cu is well characterized within the broader copper-peptide literature. The coordination of copper(II) by the histidine imidazole nitrogen and the deprotonated amide nitrogens of the peptide backbone produces a defined complex with characteristic spectroscopic features. The stability of the complex under physiological conditions is high, and the complex retains its defined chemistry across the conditions typically used in cell-culture research.

The published basic-research literature on AHK-Cu specifically — though smaller in volume than the literature on GHK-Cu — has continued to refine the characterization of the compound's effects in dermal papilla cell and hair-follicle research models. Comparative work alongside GHK-Cu and other small copper peptides has helped place AHK-Cu within the broader research family and has informed the understanding of how differences in amino acid sequence influence cellular effects.

Unlike GHK-Cu, AHK-Cu has not been the subject of a substantial clinical-development program for any specific indication. The compound has remained primarily a research tool used in basic-research investigations and in cosmetic-research contexts rather than in pharmaceutical-approval clinical trials. The honest framing is that the basic-research literature characterizes the compound's bioinorganic chemistry and its effects in laboratory research models, but the clinical evidence base for any specific indication is limited and the compound is not an approved medicine.

Methodologically, AHK-Cu research has used dermal papilla cell-culture systems, related dermatology-relevant cell-culture models, and animal-model investigations in various experimental contexts. The compound's characterization includes detailed bioinorganic studies of the copper coordination, comparative work with related small copper peptides, and applications-focused research in dermal papilla cell biology and hair-follicle research.

Open questions in the field include the precise molecular mechanism by which AHK-Cu produces its observed effects in dermal papilla cells (copper delivery versus peptide-specific signaling, or both); the detailed comparative pharmacology of AHK-Cu and GHK-Cu in side-by-side experimental settings; the broader question of how small copper peptides relate to the broader biology of cellular copper handling; and the question of whether the laboratory findings in dermal papilla cell models translate into meaningful effects in more complex tissue and whole-organism contexts.

For students, researchers, and curious readers approaching AHK-Cu for the first time, the most accurate framing is that of a small copper-binding tripeptide complex with a well-defined chemistry, a focused research niche in dermal papilla cell biology, a research literature that builds on the broader copper-peptide research family, and no established clinical role. The compound is supplied for laboratory and analytical use only, and educational discussion of it needs to stay within that framing rather than drift into implied hair-loss treatment claims or cosmetic efficacy claims.

AHK-Cu is a small synthetic tripeptide-copper complex consisting of the three amino acids alanine, histidine, and lysine bound to a copper(II) ion. The compound belongs to the small copper-peptide research family that also includes the more extensively studied GHK-Cu, sharing the central histidine-anchored copper coordination motif. The copper(II) ion is held in place by coordination to the histidine imidazole nitrogen and the deprotonated amide nitrogens of the peptide backbone, producing a defined complex with characteristic blue or purple-blue color from the d-d electronic transitions of the copper ion in the peptide coordination environment.

The published research on AHK-Cu has focused primarily on dermal papilla cell biology and hair-follicle research in cell-culture and animal-model systems. The compound has been used as a tool for studying cell signaling, gene expression, and cell-culture morphology in these dermatology-related systems. Comparative work alongside GHK-Cu and other small copper-binding peptides has placed AHK-Cu within the broader research family and informed the understanding of how differences in amino acid sequence influence the cellular effects of small copper-peptide complexes. The detailed molecular mechanism by which AHK-Cu produces its observed effects in research models — whether through copper delivery to cellular targets, peptide-specific signaling, or both — is not fully resolved and continues to be a topic of investigation.

Unlike GHK-Cu, AHK-Cu has not been the subject of a substantial clinical-development program for any specific indication. The compound has remained primarily a research tool used in basic-research investigations and in cosmetic-research contexts rather than in pharmaceutical-approval clinical trials. The honest framing is that the basic-research literature characterizes the compound's bioinorganic chemistry and its effects in laboratory research models, but the clinical evidence base for any specific indication is limited and the compound is not an approved medicine. It is not an approved hair-loss treatment, and educational discussion of it needs to stay within the research framing rather than drift into implied hair-loss treatment claims or cosmetic efficacy claims.

The most important educational point about AHK-Cu is the combination of well-defined chemistry, focused research niche, and limited clinical evidence. The bioinorganic chemistry of the copper-peptide complex is characterized in detail; the research applications in dermal papilla cell biology and hair-follicle research are specific and well-defined; but the translation of laboratory findings into clinical applications has not been pursued through pharmaceutical-approval pathways. The compound is supplied for laboratory and analytical use only.

For students, researchers, and curious readers approaching AHK-Cu for the first time, the most accurate framing is that of a small copper-binding tripeptide complex with a well-defined chemistry, a focused research niche in dermal papilla cell and hair-follicle biology, a research literature that builds on the broader copper-peptide research family, and no established clinical role. Reading the broader copper-peptide research literature — particularly the foundational work on GHK-Cu by Loren Pickart and colleagues — provides essential context for understanding AHK-Cu's place in the field.